Aqr Capital Management LLC Revance Therapeutics, Inc. Transaction History

Aqr Capital Management LLC

$75.6 Billion
Q4 2024

A detailed history of Aqr Capital Management LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 78,988 shares of RVNC stock, worth $202,999. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,988

Previous 99,187 20.36%

Holding current value

$202,999

Previous $254,000 20.47%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	N/A	-20,199 Reduced 20.36%	78,988 $202,000
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $261,865 - $261,865	-101,893 Reduced 50.67%	99,187 $254,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $400,046 - $808,640	170,960 Added 567.6%	201,080 $516,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $140,058 - $280,417	30,120 New	30,120 $148,000
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $17,709 - $26,966	-717 Reduced 5.05%	13,483 $341,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $260,712 - $500,834	14,200 New	14,200 $457,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $120,749 - $270,088	-9,691 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $174,655 - $207,501	-6,517 Reduced 40.21%	9,691 $287,000
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $33,305 - $41,538	-1,386 Reduced 7.88%	16,208 $453,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $59,625 - $72,181	-2,547 Reduced 12.65%	17,594 $499,000
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $158,846 - $234,543	6,838 Added 51.4%	20,141 $506,000
Q2 2020 Aug 17, 2020	BUY	$12.6 - $26.55 $167,617 - $353,194	13,303 New	13,303 $325,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $146,033 - $201,826	-8,086 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$23.55 - $30.1 $121,588 - $155,406	-5,163 Reduced 38.97%	8,086 $201,000
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $1,070 - $1,300	39 Added 0.3%	13,249 $364,000
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $10,377 - $13,314	356 Added 2.77%	13,210 $407,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $60,466 - $89,406	2,463 Added 23.7%	12,854 $460,000
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $234,317 - $291,987	10,391	10,391 $286,000

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Revance Therapeutics, Inc. Transaction History